DBV Technologies Shares Up 4.26% at Midday: Record Annual Increase
DBV Technologies shares rose by 4.26% this Wednesday midday, reaching 4.16 euros. The French biotech company, specializing in the treatment of food allergies, is experiencing a remarkable stock market trajectory with a 389.4% increase over twelve months. This upward trend follows a major fundraising completed in mid-January after the announcement of encouraging clinical results in December 2025.
Significant Fundraising and Clinical Success
The biopharmaceutical laboratory has raised a gross amount of 166.7 million euros following the full exercise of warrants issued from a financing mechanism launched last March. These warrants were exercisable until January 15, 2026, thirty days after the publication of the positive preliminary results of the VITESSE clinical study. The Phase 3 VITESSE trial met its primary endpoint with 46.6% of treated children meeting the criteria after twelve months, compared to 14.8% in the placebo group.
This influx of liquidity is intended to finance operations and preparations for the launch of the VIASKIN patch for peanut allergies in children aged 4 to 7 in the United States, pending regulatory approval. The management plans to submit the biological license application to the FDA in the first half of 2026, a deadline that the market is watching closely. JP Morgan Chase exceeded the 10% ownership threshold in early January 2026, now holding 13.20% of the capital and voting rights, demonstrating institutional investors' confidence in the company.
Strong Market Indicators and Analyst Confidence
The stock is now trading above its three strategic moving averages, indicating sustained positive momentum: the price of 4.16 euros exceeds the MM20 at 3.41 euros, the MM50 at 3.03 euros, and the MM200 at 2.14 euros. The RSI indicator is at 72, slightly entering the overbought zone, which calls for caution regarding an immediate continuation of the rise without prior consolidation. The stock is also approaching a technical resistance threshold at 4.27 euros, a breakthrough of which could open new upward horizons.
The MACD shows constructive signals with a MACD line at 0.27 above the signal line at 0.21, confirming the strength of the current trend. Kempen maintains its buy recommendation on the French biotech, raising its price target from 6.50 euros to 11 euros in mid-December, representing a theoretical potential of 164% compared to the last quoted price. However, investors should keep in mind that the company faces cash constraints: the company estimates that its financial availability is sufficient only until the third quarter of 2026, not covering the next twelve months, thus creating uncertainty about the continuity of operations.
